ArticleTranslational lung cancer research2026
Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Case Description: A 49-year-old male patient with a history of heavy smoking experienced an insidious onset of symptoms, including a painful left lower-limb mass, dyspnea, chest tightness, and hoarseness. Diagnosis of SMARCA4-UT was confirmed by genetic testing of cancer and immunohistochemistry. The patient received four cycles of tislelizumab combined with albumin-bound paclitaxel and carboplatin, followed by four cycles of tislelizumab monotherapy maintenance. Multiplex immunofluorescence (mIF) staining was performed on the subcutaneous metastatic lesion tissue of the left lower limb to detect the expression patterns of six target molecules [CD20, CD56, CD8, programmed cell death protein 1 (PD-1), CD68, and pan-CK], with ZEN software (Zeiss) being used for qualitative and quantitative analysis. The patient's general condition improved significantly after treatment; dyspnea, chest tightness, and left lower-limb pain were resolved; and the best therapeutic response was partial response. mIF staining revealed varying intensities of positive signals for all six target markers in the subcutaneous metastatic lesion: CD56, PD-1, and pan-CK exhibited high expression, while CD8, CD68, and CD20 exhibited low expression. Conclusions: SMARCA4-UT has an insidious onset and a diversity of metastatic sites, which can easily result in misdiagnosis, and genetic testing of cancer and immunostaining for SMARCA4 are crucial for achieving an accurate diagnosis. The distinct marker expression profile in subcutaneous metastatic lesions (high CD56, PD-1, and pan-CK expression with low CD8, CD68, and CD20 expression) reflects the unique TME of SMARCA4-UT, which may be related to its metastatic potential and immunotherapeutic response. Chemotherapy combined with immunotherapy shows promising efficacy in the treatment of SMARCA4-UT, and the mIF-based marker profile may provide a potential basis for optimizing individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.